BIOR

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of five abstracts for presentation at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting. ACG’s mission is to advance world-class care for patients with gastrointestinal disorders through excellence, innovation, and advocacy in the areas of scientific investigation, education, prevention, and treatment. The 2022 ACG Annual Scientific Meeting will be held in Charlotte, NC and virtually from October 21–26, 2022.

Targeted Therapeutics Platform Poster PresentationsBiora will be presenting results of its device performance studies in healthy volunteers and active UC patients, as well as PK/PD data on enema dosing with adalimumab in active UC patients. Details of the presentations are as follows:

Poster Number:		B0402
Session:		Scientific Poster Session B
Date:		Monday, October 24, 2022, 10:00 AM – 12:00 PM
Presenting Author:		Shaoying Nikki Lee, PhD, Associate Director, Clinical and Translational Science, Biora Therapeutics, Inc.

Poster Number:		D0390
Session:		Scientific Poster Session D
Date:		Tuesday, October 25, 2022, 10:00 AM – 12:00 PM
Presenting Author:		Jakob Begun, MD, PhD, Associate Professor, IBD Group Leader Mater Research Institute, University of Queensland, Australia

Poster Number:		E0341
Date:		Tuesday, October 25, 3:00 PM – 5:00 PM
Session:		Poster Session E
Presenting Author:		Kathleen Martin, MD CHI St. Joseph Medical Group - Gastroenterology

Systemic Therapeutics Platform Poster PresentationsBiora will be presenting preclinical model development and preclinical data for its systemic therapeutics platform. Details of the presentations are as follows:

Poster Number:		B0635
Session:		Scientific Poster Session B
Date:		Monday, October 24, 2022, 10:00 AM – 12:00 PM
Presenting Author:		Shaoying Nikki Lee, PhD, Associate Director, Clinical and Translational Science, Biora Therapeutics, Inc.

Poster Number:		D0637
Session:		Scientific Poster Session D
Date:		Tuesday, October 25, 2022, 10:00 AM – 12:00 PM
Presenting Author:		Cheryl Stork, PhD, Scientist II, Preclinical Translation, Biora Therapeutics, Inc.

All research presented at ACG 2022, including abstract titles, is strictly embargoed until Sunday, October 23 at 3:30 PM, EDT. Accepted abstracts will appear in a special supplement to the October 2022 issue of The American Journal of Gastroenterology. Poster presentations will also be made available on the Biora Therapeutics website.

About Biora TherapeuticsBiora Therapeutics is the biotech company that is reimagining therapeutics. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives. Biora envisions a world where patients have access to needle-free drug delivery and better therapeutic outcomes.

For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter.

Safe Harbor Statement or Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of precision medicine, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding future revenue generating opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, the ongoing COVID-19 pandemic, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor ContactChuck PadalaManaging Director, LifeSci AdvisorsIR@bioratherapeutics.com(646) 627-8390

Media Contactmedia@bioratherapeutics.com